Qube Research & Technologies (QRT)
DNTH icon

Qube Research & Technologies (QRT)’s Dianthus Therapeutics DNTH Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.55M Buy
30,354
+20,060
+195% +$1.16M ﹤0.01% 2033
2025
Q4 		$424K Buy
+10,294
New +$399K ﹤0.01% 2849
2024
Q4 		– Sell
-7,753
Closed -$212K – 3537
2024
Q3 		$212K Sell
7,753
-3,452
-31% -$96.2K ﹤0.01% 2567
2024
Q2 		$290K Sell
11,205
-56,641
-83% -$1.36M ﹤0.01% 2318
2024
Q1 		$2.04M Buy
67,846
+67,044
+8,360% +$1.46M ﹤0.01% 1747
2023
Q4 		$8.34K Buy
802
+799
+26,633% +$8.83K ﹤0.01% 3632
2023
Q3 		$41 Buy
+3
New +$38 ﹤0.01% 3832
2022
Q4 		– Sell
-1,276
Closed -$29K – 2572
2022
Q3 		$29K Sell
1,276
-129
-9% -$3.53K ﹤0.01% 2242
2022
Q2 		$27K Buy
+1,405
New +$34.7K ﹤0.01% 2222
2021
Q3 		– Sell
-818
Closed -$128K – 2330
2021
Q2 		$128K Buy
+818
New +$150K ﹤0.01% 1896

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Qube Research & Technologies (QRT)'s DNTH Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its Dianthus Therapeutics (DNTH) stake by 195% in Q1 2026, buying an estimated $1.16M and bringing the position to 30,354 shares worth $2.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2033.

Qube Research & Technologies (QRT) first reported a position in DNTH in Q2 2021 and has held it in 10 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Qube Research & Technologies (QRT) held 30,354 shares of Dianthus Therapeutics worth $2.55M as of Q1 2026.
  • Qube Research & Technologies (QRT) bought 20,060 Dianthus Therapeutics shares in Q1 2026, an estimated $1.16M.
  • Dianthus Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #2033 holding.
  • Qube Research & Technologies (QRT) first reported a position in Dianthus Therapeutics in Q2 2021 and has held it in 10 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.